scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company specializing in optimized delivery of infused therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. John Tucker, the company's President & CEO, is scheduled to present on Wednesday, September 11 at 10:00AM ET.
In addition to the presentation, Mr. Tucker will be engaging in investor meetings throughout the day. Interested parties can access a webcast of the presentation via a provided link or through the 'News & Events' section of scPharmaceuticals' official website.
This event provides an opportunity for scPharmaceuticals to showcase its progress in developing products aimed at advancing patient care and reducing healthcare costs through innovative infusion therapy delivery methods.
scPharmaceuticals Inc. (Nasdaq: SCPH), un'azienda farmaceutica specializzata nella somministrazione ottimizzata di terapie infusionali, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. John Tucker, Presidente e CEO dell'azienda, è programmato per presentare il mercoledì 11 settembre alle 10:00 ET.
Oltre alla presentazione, il signor Tucker parteciperà a incontri con gli investitori durante tutta la giornata. Le parti interessate possono accedere a un webcast della presentazione tramite un link fornito o attraverso la sezione 'News & Events' del sito ufficiale di scPharmaceuticals.
Questo evento offre a scPharmaceuticals l'opportunità di mostrare i suoi progressi nello sviluppo di prodotti mirati a promuovere l'assistenza ai pazienti e ridurre i costi sanitari attraverso metodi innovativi di somministrazione della terapia infusionale.
scPharmaceuticals Inc. (Nasdaq: SCPH), una empresa farmacéutica especializada en la entrega optimizada de terapias por infusión, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. John Tucker, el Presidente y CEO de la empresa, está programado para presentar el miércoles 11 de septiembre a las 10:00 AM ET.
Además de la presentación, el Sr. Tucker participará en reuniones con inversores durante todo el día. Las partes interesadas pueden acceder a un webcast de la presentación a través de un enlace proporcionado o en la sección 'News & Events' del sitio web oficial de scPharmaceuticals.
Este evento brinda a scPharmaceuticals la oportunidad de mostrar su progreso en el desarrollo de productos destinados a avanzar en la atención al paciente y reducir los costos de atención médica mediante métodos innovadores de entrega de terapia por infusión.
scPharmaceuticals Inc. (Nasdaq: SCPH), 주입 치료의 최적화된 전달을 전문으로 하는 제약 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. John Tucker, 회사의 사장 겸 CEO는 9월 11일 수요일 오전 10:00 ET에 발표할 예정입니다.
발표 외에도 Tucker 씨는 하루 종일 투자자와의 회의에 참여할 예정입니다. 관심 있는 분들은 제공된 링크를 통해 또는 scPharmaceuticals 공식 웹사이트의 'News & Events' 섹션을 통해 발표의 웹캐스트에 접속할 수 있습니다.
이번 행사에서는 scPharmaceuticals가 환자 치료를 향상하고 의료 비용을 줄이는 것을 목표로 하는 제품 개발의 진전을 보여줄 수 있는 기회를 제공합니다.
scPharmaceuticals Inc. (Nasdaq: SCPH), une entreprise pharmaceutique spécialisée dans la livraison optimisée des thérapies par infusion, a annoncé sa participation à la 26e Conférence mondiale annuelle d’investissement H.C. Wainwright. John Tucker, le président-directeur général de l'entreprise, doit faire une présentation le mercredi 11 septembre à 10h00 ET.
En plus de la présentation, M. Tucker participera à des réunions avec les investisseurs tout au long de la journée. Les parties intéressées peuvent accéder à un webcast de la présentation via un lien fourni ou dans la section 'News & Events' du site officiel de scPharmaceuticals.
Cette événement offre à scPharmaceuticals l’occasion de mettre en avant ses progrès dans le développement de produits visant à améliorer les soins aux patients et à réduire les coûts de santé grâce à des méthodes innovantes de délivrance de thérapies par infusion.
scPharmaceuticals Inc. (Nasdaq: SCPH), ein Pharmaunternehmen, das sich auf die optimierte Abgabe von Infusionstherapien spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. John Tucker, der Präsident und CEO des Unternehmens, wird voraussichtlich am Mittwoch, den 11. September um 10:00 Uhr ET präsentieren.
Zusätzlich zur Präsentation wird Herr Tucker den ganzen Tag über Investorenmeetings durchführen. Interessierte Parteien können über einen bereitgestellten Link oder über den Abschnitt 'News & Events' der offiziellen Website von scPharmaceuticals auf ein Webcast der Präsentation zugreifen.
Diese Veranstaltung bietet scPharmaceuticals die Gelegenheit, seine Fortschritte bei der Entwicklung von Produkten zu zeigen, die darauf abzielen, ddie Patientenversorgung zu verbessern und die Gesundheitskosten zu senken, durch innovative Methoden zur Abgabe von Infusionstherapien.
- None.
- None.
BURLINGTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00AM ET. Mr. Tucker will also be meeting with investors that day.
A webcast of the presentation can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
PJ Kelleher
LifeSci Advisors, 617-430-7579
pkelleher@lifesciadvisors.com
FAQ
When is scPharmaceuticals (SCPH) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for scPharmaceuticals (SCPH) at the investment conference?
How can investors access the scPharmaceuticals (SCPH) presentation at the H.C. Wainwright conference?
What is the focus of scPharmaceuticals (SCPH) as a company?
